USP9Y

Across TCGA pan-cancer cohorts, USP9Y Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated USP9Y data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher USP9Y Mutation is associated with better overall survival. In most high-consensus cancer types, elevated USP9Y expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

BLCA, LIHC, and PRAD are the cancer types where USP9Y Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.826	0.344	.017	18	view →
LIHC	OS	Median	All	0.128	0.707	<.001	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	IV	0.179	0.755	<.001	6	view →
ESCA	DFS	Median	All	0.146	0.533	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

USP9Y–BLCA (OS)

Open the BLCA breakdown →